CA3182133A1 - Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof - Google Patents
Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereofInfo
- Publication number
- CA3182133A1 CA3182133A1 CA3182133A CA3182133A CA3182133A1 CA 3182133 A1 CA3182133 A1 CA 3182133A1 CA 3182133 A CA3182133 A CA 3182133A CA 3182133 A CA3182133 A CA 3182133A CA 3182133 A1 CA3182133 A1 CA 3182133A1
- Authority
- CA
- Canada
- Prior art keywords
- oxo
- dihydroquinazolin
- urea
- methoxyethyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202011027502A IN202011027502A (enExample) | 2020-06-29 | 2020-06-29 | |
| IN202011027502 | 2020-06-29 | ||
| PCT/IN2021/050621 WO2022003712A1 (en) | 2020-06-29 | 2021-06-25 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3182133A1 true CA3182133A1 (en) | 2022-01-06 |
Family
ID=79315704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3182133A Pending CA3182133A1 (en) | 2020-06-29 | 2021-06-25 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12528777B2 (enExample) |
| EP (1) | EP4171569A4 (enExample) |
| AU (1) | AU2021301444A1 (enExample) |
| CA (1) | CA3182133A1 (enExample) |
| IN (1) | IN202011027502A (enExample) |
| WO (1) | WO2022003712A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4452952A4 (en) * | 2021-12-25 | 2025-12-03 | Council Of Scient And Industrial Research An Indian Registered Body Incorporated Under Regn Of Soc A | PREPARATION OF QUINAZOLINEDIONES AND THEIR USE |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1280874B (de) * | 1963-10-09 | 1968-10-24 | Boehringer Sohn Ingelheim | 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4) |
| US20080255161A1 (en) * | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| CN101531638B (zh) | 2008-03-13 | 2011-12-28 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| JP2012505881A (ja) | 2008-10-15 | 2012-03-08 | ギリアード サイエンシーズ， インコーポレイテッド | ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するための３−ヒドロキナゾリン−４−オン誘導体 |
| PL3386591T3 (pl) * | 2015-12-09 | 2021-02-22 | Novartis Ag | Heteroaromatyczne modulatory receptorów nmda i ich zastosowania |
| KR101932146B1 (ko) | 2016-07-14 | 2018-12-24 | 주식회사 바이오웨이 | Pi3k를 억제하는 신규한 퀴나졸리논 유도체 및 이를 포함하는 약학적 조성물 |
| CA3186951A1 (en) * | 2020-07-24 | 2022-01-27 | Joshua Odingo | Quinazolinone hsd17b13 inhibitors and uses thereof |
-
2020
- 2020-06-29 IN IN202011027502A patent/IN202011027502A/en unknown
-
2021
- 2021-06-25 US US18/013,681 patent/US12528777B2/en active Active
- 2021-06-25 CA CA3182133A patent/CA3182133A1/en active Pending
- 2021-06-25 WO PCT/IN2021/050621 patent/WO2022003712A1/en not_active Ceased
- 2021-06-25 EP EP21833670.9A patent/EP4171569A4/en active Pending
- 2021-06-25 AU AU2021301444A patent/AU2021301444A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4171569A4 (en) | 2024-07-03 |
| US20230357165A1 (en) | 2023-11-09 |
| AU2021301444A1 (en) | 2022-11-24 |
| WO2022003712A1 (en) | 2022-01-06 |
| US12528777B2 (en) | 2026-01-20 |
| EP4171569A1 (en) | 2023-05-03 |
| IN202011027502A (enExample) | 2021-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6799624B2 (ja) | ＩＲＥ−１αインヒビター | |
| JP7490781B2 (ja) | Ｓａｒｍ１の阻害剤 | |
| JP6618120B2 (ja) | ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体 | |
| TWI676620B (zh) | 離胺酸特異性去甲基酶-１之抑制劑 | |
| JP5313125B2 (ja) | スルホンアミド誘導体 | |
| JP5087406B2 (ja) | 治療薬ならびにその製造方法および使用方法 | |
| JP6812059B2 (ja) | ＴｒｋＡ阻害活性を有する複素環誘導体 | |
| CA3189181A1 (en) | Inhibitors of sarm1 | |
| JP2011526295A (ja) | ５員および６員複素環化合物 | |
| JPWO2006046779A1 (ja) | カルバゾール誘導体、その溶媒和物、又は薬学的に許容されるその塩 | |
| US20170057942A1 (en) | Isoquinoline derivatives and use thereof | |
| CA3114883A1 (en) | Matriptase 2 inhibitors and uses thereof | |
| US10738031B2 (en) | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | |
| CN103857668A (zh) | 作为mglur5变构调节剂的乙炔基衍生物 | |
| TW201102375A (en) | Hedgehog pathway antagonists and therapeutic applications thereof | |
| KR20170106294A (ko) | Dpp-4 억제제인 벤조 6원 고리 유도체 및 이의 응용 | |
| WO2000021934A1 (en) | Compounds | |
| US5739127A (en) | 2,4'-bridged bis-2,4-diaminoquinazolines | |
| CN113956182A (zh) | Hdac/mao-b双重抑制剂及其制备和应用 | |
| EP1124821A1 (en) | Compounds | |
| CN116283918B (zh) | 一种降解受体酪氨酸激酶的双功能化合物及其应用 | |
| CA3182133A1 (en) | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | |
| CN103508960A (zh) | 苯并杂环衍生物 | |
| CA2897924A1 (en) | Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors | |
| CA3088968C (en) | Dihydroindolizinone derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241022 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250527 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250528 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250528 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250530 |